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Postprimary tuberculosis occurs in immunocompetent people infected with Mycobacterium tuberculosis. It is restricted to the lung
and accounts for 80% of cases and nearly 100% of transmission. Little is known about the immunopathology of postprimary
tuberculosis due to limited availability of specimens. Tissues from 30 autopsy cases of pulmonary tuberculosis were located.
Sections of characteristic lesions of caseating granulomas, lipid pneumonia, and cavitary stages of postprimary disease were
selected for immunohistochemical studies of macrophages, lymphocytes, endothelial cells, and mycobacterial antigens. A higher
percentage of cells in lipid pneumonia (36.1%) and cavitary lesions (27.8%) were positive for the dendritic cell marker DEC-205,
compared to granulomas (9.0%, P < .05). Cavities contained significantly more T-regulatory cells (14.8%) than found in lipid
pneumonia (5.2%) or granulomas (4.8%). Distribution of the immune cell types may contribute to the inability of the immune
system to eradicate tuberculosis.
1. Introduction
Mycobacterium tuberculosis (MTB) is endemic in every
part of the world. This organism accounts for nearly 2
million deaths annually, making it the leading bacterial cause
of death worldwide [1]. Once thought to be controlled,
tuberculosis (TB) incidence is rising in many areas caused
in part by the emergence of drug-resistant strains and the
HIV epidemic. Furthermore, nearly one-third of the world
is latently infected with MTB, making eradication of the
organism diﬃcult.
MTB infection begins as primary TB with the depo-
sition of bacilli in the alveoli, which are phagocytosed
by alveolar macrophages [2]. Numerous animal models of
primary TB are available and much is known about the
immune responses that drive granuloma development [3].
Macrophage production of TNF-α and chemokines recruits
systemic monocytes which form the nascent granuloma.
Adaptive immunity develops after infected dendritic cells
(DCs) migrate to a draining lymph node [4, 5]. Neu-
trophils may also facilitate the presentation and migration
of mycobacterial antigens to draining lymph nodes [6]. IL-
12 production by DCs promotes the development of IFN-
γ Th1 cells that activate macrophages, thereby stabilizing
bacterial growth [3]. The development of an acquired
immune response results in the formation of a mature
caseating granuloma that consists of central necrosis and
infected macrophages surrounded by epitheliod and foamy
macrophages and an outer layer of fibrosis associated with
lymphocytes [7]. Most of such lesions heal, but viable organ-
isms persist. Patients at this stage of infection are considered
latently infected because they lack clinical symptoms and
have stable chest X-rays, and sputums are negative for acid-
fast bacilli [8]. The TB bacilli persist, despite the strong
immune response needed to generate granulomas. This is
possibly explained by the finding that the acquired immune
response toMTB is delayed in comparison to other infectious
diseases [9].
A fraction of latently infected individuals develop
reactivation of infection or are reinfected from the
environment [10]. Such infection of a previously immune
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or sensitized person produces a very diﬀerent type of disease
known as postprimary TB (also referred to as adult type or
secondary infection). Postprimary TB is typically restricted
to the lung where it produces cavities that are responsible
for 80% of all TB disease and virtually 100% of transmission
of the bacilli from person to person [11]. Postprimary TB
occurs characteristically in young immunocompetent adults
with suﬃcient immunity to control primary TB [12].
It is a paradigm of contemporary research that caseating
granulomas are the characteristic lesion of both primary
and postprimary TB and that cavities form by expansion
of caseating granulomas with softening and liquefaction of
their contents that are discharged as they erode into bronchi.
We previously reported studies of untreated primary and
postprimary TB that contradicted this paradigm [13]. Based
on our observations from preantibiotic era derived samples,
we hypothesized that postprimary TB begins as a lipid
pneumonia in which infection is restricted to foamy alveolar
macrophages. Therefore, resultant cavities appeared to result
from necrosis of tuberculous pneumonia in individuals
who had no histologic evidence of caseating granulomas.
The present studies were undertaken to characterize the
cellular makeup of each of the characteristic stages of human
pulmonary TB in immunocompetent adults. We examined
slides of the lungs of 30 people who died of pulmonary
TB and selected representative sections of each of the major
stages of the disease. These were (1) caseating granulomas
of primary TB, (2) lipid pneumonia, and (3) cavitary
lesions. These sections were studied with immunohisto-
chemical markers of T-cell subsets, macrophages, DCs, and
endothelial cells based on published studies of these markers
in animal models of TB. Immunohistochemical analysis
of MTB antigens and acid fast bacilli (AFB) staining was
included to explore our hypothesis that a progressive buildup
of mycobacterial antigens precedes and contributes to the
rapid necrosis of caseous pneumonia [11]. These studies
were accomplished with a multispectral imaging microscope
and image analysis software that facilitates accurate diﬀeren-
tiation and quantitation of multiple cell types with precise
quantitation of immunohistochemical markers.
The results demonstrate distinct patterns of immune cells
in each of the stages of pulmonary TB. Foamy macrophages
(FMs) found in lipid pneumonia and in the walls of cavitary
lesions were frequently positive for the DCmarker DEC-205.
An increased percentage of T-regulatory (Treg) cells in the
cavity walls of TB provide evidence of an active role in the
disease process. It is hypothesized that the local accumulation
of immune cells with suppressive properties may contribute
to the chronic nature of MTB infection.
2. Methods
2.1. Tissue Specimens. Formalin-fixed, paraﬃn-embedded
tissue blocks from patients with postprimary TB were
obtained from the First Infectious Disease Hospital, St.
Petersburg, Russian Federation. Specimens were from
archived cases of autopsies of patients who had died of
pulmonary TB and were culture positive for MTB or
had positive stains for acid-fast bacilli. Thirty cases of
postprimary TB patients were available for investigation.
Although detailed information is not available, all patients
were HIV negative. All cases were stained with hematoxylin
and eosin and acid fast stained by the Ziehl-Neelsen method
per standard protocols.
This study was conducted according to the princi-
ples expressed in the Declaration of Helsinki. The study
was approved by the Institutional Review Board of UT-
Houston Medical School IRB protocol number HSC-MS-
10-0109, Immunopathology of Tuberculosis. We studied
microscope slides of tissues from patients with tuberculosis.
All materials were byproducts of regular autopsy practice and
were obtained after completion of all medical needs. The
specimens were deidentified for the study.
2.2. Immunohistochemistry Staining for Immune Cell Markers.
Five-μm tissue sections were deparaﬃnized and stained
with monoclonal antibodies for CD4 (Leica-Microsystems,
Bannockburn, IL), CD8 (Dako, Carpinteria, CA), CD20
(Dako), CD31 (Leica-Microsystems), CD68 (Dako), DEC-
205 (Santa Cruz Biotechnology, Santa Cruz, CA), and Foxp3
(Abcam, Cambridge, MA). Mouse monoclonal antibodies
were used for all immune cell markers. A rabbit polyclonal
antibody to purified protein derivative (Abcam) was used
for the detection of MTB. The pretreatments, dilutions,
and incubation times are shown in Table 1. After washing,
sections were incubated for one hour with antimouse (Dako)
or antirabbit (Biocare Medical, Concord, CA) polyclonal
antibodies labeled with HRP.
2.3. Photography and Image Analysis. All images were taken
using the Nuance multispectral imaging system (CRI,
Woburn, MA), which allowed enumeration of cellular
phenotypes in defined areas of pathology. Three distinct
pathologic manifestations of TB were analyzed that included
granulomas, lipid pneumonia, and cavitary lesions. Images
from at least 5 cases of the defined pathological manifesta-
tions were captured with the 10x objective. Quantification
of immune cells expressing specific markers was performed
with the tissue and cell segmenting functions of Inform
software (CRI), according to themanufacturer’s instructions.
The total number of cells in an image was determined using
the hematoxylin stain.
3. Results
3.1. Granulomatous Pathology. Three distinct patterns of
pathology of pulmonary TB were analyzed. The first type
is the caseating granuloma characteristic of primary TB.
Similar caseating granulomas were observed in primary TB,
miliary TB, and chronic fibrocaseous postprimary TB. A
representative image is shown in Figure 1(a). A central region
of caseous necrosis is surrounded by foamy and epitheliod
macrophages, often presenting with Langhan’s giant cells
(Figure 1(b)). The percentages of diﬀerent immune cell
markers obtained by quantitative image analysis are shown
in Table 2. Granulomas contained an abundance of CD68+
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Table 1: Conditions for immunohistochemistry staining of immune cell markers and MTB.
Marker Pretreatment Dilution Incubation timea
CD4 steam for 20 minutes in EDTA, pH 8.0 1 : 25 45
CD8 steam for 20 minutes in EDTA, pH 8.0 1 : 125 30
CD20 5 minutes under pressure in citrate buﬀer, pH 6.0 1 : 800 20
CD31 5 minutes under pressure in citrate buﬀer, pH 6.0 1 : 100 30
CD68 5 minutes under pressure in citrate buﬀer, pH 6.0 1 : 2000 20
DEC-205 steam for 20 minutes in EDTA, pH 8.0 1 : 50 overnight
Foxp3 5 minutes under pressure in citrate buﬀer, pH 6.0 1 : 100 30
MTB Proteinase K 1 : 100 60
a
minutes.
(a) (b)
CD4
(c)
CD8
(d)
CD20
(e)
CD68
(f)
DEC205
(g)
Foxp3
(h)
CD31
(i)
Figure 1: Granuloma histopathology. (a) Typical caseating granuloma, with central necrosis flanked by epitheliod cells and foamy
macrophages. The periphery of the granuloma consists of lymphocytes, 100x. (b) Langhan’s giant cell, 400x. (c) Abundant CD4+ cells
in the granuloma include both lymphocytes and macrophages, 100x. (d) CD8+ cells were mainly located in the periphery of the granuloma,
100x. (e) B-cells, identified by the CD20 stain, were noted in the outer layer of the granuloma. (f) Granulomas stained heavily for the CD68
marker, 100x. (g) Macrophages at the periphery of the granuloma stain positive for the dendritic cell marker DEC-205, 400x. The insert
demonstrates a digitally zoomed region to detail the DEC-205 staining. (h) T-regulatory cells, identified by the Foxp3 marker (arrow), were
found in the lymphocytic layer of the granuloma, 400x. (i) CD31 stain shows well-vascularized tissue at the periphery of the granuloma,
200x.
4 Clinical and Developmental Immunology
macrophages and CD4+ lymphocytes (Figures 1(f) and
1(c)). CD8+ lymphocytes, as well as B-cells identified by the
CD20 marker, were found in the lymphocytic outer region
of the granuloma (Figures 1(d) and 1(e)). The outermost
layer of the granuloma near the alveoli consisted of FMs
that were frequently positive for the DC marker DEC-
205 (Figure 1(g)). Foxp3, a marker for Treg cells, were
occasionally noted interspersed between other stained lym-
phocytes (Figure 1(h)). The periphery of granulomas was
well-vascularized as assessed by the CD31 stain (Figure 1(i)).
3.2. Lipid Pneumonia. The alveoli were filled with FMs
positive for the CD68 marker with lymphocytes present in
the alveolar walls (Figures 2(a)–2(c)). Cells in the alveoli
occasionally had a “dry” appearance with areas of fibrosis
(Figure 2(a)) or a homogenous consistency of necrotic
material (Figure 2(c)). Bronchial obstruction was frequently
present [13]. CD4+ cells were present at significantly less
frequency compared to numbers seen in granulomas (P
< .05, Table 2 and Figure 2(d)). CD8+ cells were frequently
observed in the alveolar walls as well as the alveoli
(Figure 2(e)). B-cells were rarely noted in the regions of lipid
pneumonia but were observed to occur in large clusters in
regions that bordered the lipid pneumonia (not shown).
The FMs in the alveoli were frequently positive for the DC
marker DEC-205 (Figure 2(g)). Treg cells were noted in the
alveoli but were scarce elsewhere (Figure 2(h)). Disrupted
lung architecture of developing caseaous necrosis was readily
apparent on the CD31 stain of vascular endothelial cells
(Figure 2(i)).
3.3. Cavitary Lesions. An example of a cavity that appears
to be developing by necrosis and fragmentation of lipid
pneumonia is shown in Figure 3(a). The cavity wall is made
up of necrotic debris, foamy macrophages, and lymphocytes.
Abundant fibrosis develops as the lesion becomes chronic
(Figure 3(b)). The lymphocytes lining the walls of mature
cavities were a mixture of CD4, CD8, and CD20 positive
cells (Table 2 and Figures 3(c)–3(e)). The FMs lining the
cavity wall were strongly positive for the DC marker DEC-
205 (Figure 3(g)). Numerous Treg cells were present around
the cavities (Figure 3(h)). The walls of the cavitary lesions
contained abundant granulation tissue (Figure 3(i)). None
of the cavitary lesions were directly associated with caseous
granulomatous pathology.
3.4. Localization of MTB Antigens and Acid-Fast Bacilli. MTB
were rarely observed in granulomas by either Zhiel-Neelsen
staining or immunohistochemistry for MTB. Representative
images from cases of lipid pneumonia and cavitary lesions
are shown in Figure 4. Early lipid pneumonia demonstrated
evidence of mycobacterial antigens throughout alveoli, but
very few acid-fast bacilli were seen (Figures 4(a)–4(c)). As the
lipid pneumonia undergoes necrosis, both abundant tuber-
culin antigens and bacilli are evident (Figures 4(d)–4(f)).
Cavities had roughly equal amounts of antigen and bacteria,
most of which were localized to regions representing the
cavity wall (Figures 4(g)–4(i)).
4. Discussion
A central question in TB research is why the immune
system successfully controls primary TB but fails to clear
a postprimary TB cavity and thus halt transmission of
infection. A problem is that investigators have little to study
since few specimens of human pulmonary TB are available
to them. Recent descriptions of specimens recovered from
surgical cases of patients with cavitary TB are available [14].
This project was built on earlier studies that described the
histopathology of the stages of postprimary TB [13]. To
our knowledge, this study is the first recent description of
postprimary TB that includes Tregs and cells with the DEC-
205 marker.
Histopathologic examination of the 30 cases in this study
supported our previous hypothesis that postprimary TB
begins as a lipid pneumonia [13]. Other authors suggest that
cavities develop when granulomas rupture into the airways
and that lipid pneumonia is a complication of cavitary
TB [2, 3, 15]. Analysis of the development of cavities is
beyond the scope of this paper. Nevertheless, a key question
of postprimary TB is how MTB survive and proliferate
in alveolar macrophages in restricted areas of lung while
the entire rest of the body remains highly immune. The
present studies provide some clues. Foamy macrophages
positive for the DC marker DEC-205 accumulate in the
alveoli with CD8+ lymphocytes in the alveolar walls and
alveoli. Ordway and colleagues [16] reported that FMs from
murine granulomas were strongly positive for the DCmarker
DEC-205. Interestingly, a high percentage of FMs found
in lipid pneumonia and those lining the cavity walls were
positive for DEC-205. The FMs in mice were reported to
have additional markers of DCs such as CD11c, MHC class
II, and CD40 as well as high levels of antiapoptotic markers
[16]. The significance of FMs expressing DC markers is
not yet clear. However, MTB-infected DCs can harbor
the bacilli for extended periods of time and do not have
eﬃcient mechanisms of eliminating MTB [17–19]. FMs with
characteristics of DCs may therefore provide a permissive
environment for the growth of mycobacteria. Furthermore,
FMs may be a tissue source of immunosuppression that
inhibits the cell-mediated immunity necessary to clear MTB.
For example, FMs secrete high levels of transforming growth
factor-beta (TGF-β) that can cause apoptosis of immune
eﬀector cells [20]. Additionally, FMs produce high levels of
inducible nitric oxide synthetase, which has been associated
with suppression of T-cells in murine MTB infection [21].
Therefore, FMs may be a contributor to the local immuno-
suppression responsible for the inability of the immune
system to eliminate postprimary TB.
Organisms in cavities typically grow in massive numbers
on the inner surface of a cavity but nowhere else in the
body even though other parts of the body, particularly
the lung, are continually exposed to large numbers of
virulent organisms being coughed into the environment. The
surface of a cavity has been described as an area of “failed
immunity” [22]. This study found a significantly increased
percentage of Treg cells in the cavitary wall compared to
other tissue manifestations of TB. Treg cells, identified by
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Table 2: Percentage of cells positive for immunological markers.
Primary TB Postprimary TB Postprimary TB
Granuloma Lipid pneumonia Cavitary lesion
Marker
CD4 30.7 ± 4.1 10.1 ± 3.1a 23.1 ± 4.6a,b
CD8 17.8 ± 4.2 19.6 ± 3.8 27.7 ± 7.1
CD20 2.0 ± 0.5 2.3 ± 0.7 7.8 ± 1.2a,b
CD68 49.4 ± 5.0 64.0 ± 12.5 55.1 ± 14.8
DEC-205 9.0 ± 3.5 36.1 ± 8.5a 27.8 ± 8.5a
Foxp3 4.8 ± 1.1 5.2 ± 1.2 14.8 ± 4.3a,b
Images of the diﬀerent tissue manifestation of TB were taken using the 10x objective from at least 5 regions of multiple cases. The total number of cells was
determined using the hematoxylin stain. The data are presented as the percentage of cells positive for a given marker, ±SD.
aP < .05, comparison to granuloma.
bP < .05, comparison to lipid pneumonia.
(a) (b) (c)
CD4
(d)
CD8
(e)
CD68
(f)
DEC205
(g)
Foxp3
(h)
CD31
(i)
Figure 2: Lipid pneumonia. (a) Alveoli are filled with macrophages and the alveolar walls have high numbers of lymphocytes, 100x. (b)
Macrophages in the lipid pneumonia have a foamy appearance, 400x. (c) The cells in the alveoli may undergo necrosis to produce a
homogenous appearance, 100x. (d) Relatively few CD4+ cells are present in lipid pneumonia, 400x. (e) Abundant CD8+ cells are noted
in the alveoli as well as in the alveolar walls, 400x. (f) Foamy cells stain strongly with the CD68 marker. (g) Foamy macrophages in the lipid
pneumonia are frequently positive for the dendritic cell marker DEC-205, 400x. The insert shows a detailed image of a DEC-205-positive
macrophage. (h) T-regulatory cells were observed in regions of lipid pneumonia (arrow), 400x. (i) The CD31 stain highlights the disrupted
lung architecture, 100x.
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(a) (b)
CD4
(c)
CD8
(d)
CD20
(e)
CD68
(f)
DEC205
(g)
Foxp3
(h)
CD31
(i)
Figure 3: Immunopathology of cavitary lesions. (a) Early cavitary lesion, surrounded by lipid pneumonia, 100x. (b) Chronic cavitary lesion.
The cavity wall consists of necrotic material, foamymacrophages, and fibrous tissue with abundant lymphocytes, 100x. (c) Numerous CD4+
cells make up the lymphocytic portion of a cavity wall, 100x. (d) CD8+ cells in the wall of a cavity, 100x. (e) CD20+ cells in the wall of a
cavitary lesion, 100x. (f) The cells lining the cavity are CD68+ macrophages, 100x. (g) Foamymacrophages lining the cavity wall are positive
for the dendritic cell marker DEC-205, 400x. Insert demonstrates a region detailing the staining for DEC-205. (h) Numerous Foxp3+ cells
(arrow) were found in the cavity wall, 400x. (i) Abundant granulation tissue in the wall of a cavitary lesion noted with the CD31 stain, 100x.
expression of the transcription factor Foxp3, are essential
for preventing self-reactive immune responses and limiting
immune-mediated tissue damage during infection [23, 24].
However, the role of Tregs in infectious diseases such as
TB is complex. Tregs produce inhibitory cytokines, such
as IL-10 and TGF-β, that protect host tissue by limiting
excess inflammation but may conversely limit clearance of
pathogens [25]. Peripheral blood Treg cells are decreased
in newly infected contacts of TB patients, possibly due
to accumulation in infected lung [26]. As the infection
progresses, Tregs expand to regions of disease sites, as well
as in blood [27–30]. Diﬀerential expression of Foxp3 in
PBMCs was predictive of active TB versus latent infection
[31]. Of significance, Foxp3 cells decreased T-cell-mediated
responses to mycobacterial antigens in human TB [32].
Depletion of Treg cells during a murine model of infection
enhanced MTB elimination [33, 34], providing further
evidence that Treg cells inhibit the clearance of MTB. A
recent study demonstrated that small numbers of MTB-
specific Tregs inhibit the accumulation of CD4 and CD8 T-
cells in the lungs of infected mice [35]. The findings from
our study demonstrate high numbers of Treg cells in a tissue
manifestation of TB from which the bacilli are frequently
not eradicated, providing further support to the hypothesis
that accumulation of Tregs at the sites of MTB infection
suppresses the activation of protective immune responses.
However, it should be noted that Treg activity was not the
limiting factor in the eﬀectiveness of BCG vaccination of
mice [36]. However, since mice do not develop cavities, the
interpretation of such studies for the human host response to
cavities must be taken with caution.
These studies also confirmed earlier observations that
large amounts of antigens of MTB demonstrable by
immunohistochemistry are present in alveoli of the lipid
Clinical and Developmental Immunology 7
(a) (b) (c)
(d) (e) (f)
(g) (h) (i)
Figure 4: Comparison of immunohistochemistry (IHC) for MTB and Zhiel-Neelsen acid fast staining. Early lipid pneumonia (a)–(c). (a)
H&E stain demonstrates macrophages and lymphocytes within the alveoli, 100x. (b) MTB are noted on the IHC, 400x. (c) Few AFB are
observed by Zhiel-Neelsen staining, 400x. Lipid pneumonia undergoing abrupt necrosis (d)–(f). (d) Cells in alveoli undergo necrosis and
have a homogenous appearance, 100x. (e) Abundant mycobacterial antigens noted on the IHC stain for MTB, 400x. (f) Numerous acid-fast
bacilli are observed, 400x. Cavitary TB (g)–(i). (g) H&E stain showing a cavity with a piece of detached lung and necrotic debris, 40x. (h)
The wall of the cavity is strongly positive for MTB antigens, 400x. (i) Acid-fast bacilli are found lining the cavity wall, 400x.
pneumonia [13]. In this stage, there was far more MTB
antigen in alveoli than organisms observed by acid-fast stain-
ing. Much of it was present in structures that were distinct
from aggregates of AFB. We hypothesize that mycobacterial
antigens accumulate progressively in alveoli during this
stage of disease. This is similar to the accumulation of
MTB antigens in alveoli of slowly progressive pulmonary
TB in mice [13]. We have proposed that this build up of
mycobacterial antigens including glycolipids is an essential
precursor to the abrupt necrosis that produces cavities [7, 37,
38].
This study has a number of important limitations. Tis-
sues from autopsy cases of patients who died of pulmonary
TB were received as deidentified paraﬃn-embedded blocks.
While we were told that the tissues came from untreated or
inadequately treated patients, detailed clinical information
on a case-by-case basis is not available. Nonetheless, this
study provides important details of the cellular phenotypes
in characteristic tissue manifestations of postprimary TB.
5. Conclusions
In summary, better understanding of the pathology of
the multiple stages of postprimary disease has facilitated
investigations of manifestations of the disease that have
heretofore been unapproachable by modern science. The
key questions are how does MTB establish and survive
in two privileged sites in the upper lobes of lungs of
hosts who are strongly immune in all other parts of the
body. The first site is an endogenous lipid pneumonia in
which MTB survive only in foamy alveolar macrophages
in parts of the lung. The second is a mature cavity in
which MTB proliferate in massive numbers on the cavitary
surface, but nowhere else. The present studies demonstrate
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that these questions can be approached with modern
quantitative immunohistochemical technologies and that
diﬀerent host responses are operative at each stage of the
disease. The results demonstrate that both types of privileged
sites are characterized by an increased percentage of cell
phenotypes with immunosuppressive properties that may
be a critical component responsible for the inability of the
immune system to clear MTB. It is anticipated that a better
understanding of the immunopathology of MTB, and the
molecular mechanisms governing the transition from latent
to active disease will ultimately lead to more eﬀective control
of TB.
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